Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Charles River Laboratories International, Inc. or CRISPR Therapeutics AG because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Charles River Laboratories International, Inc. and CRISPR Therapeutics AG compare based on key financial metrics to determine which better meets your investment needs.

About Charles River Laboratories International, Inc. and CRISPR Therapeutics AG

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Latest Life Sciences Tools & Services and Charles River Laboratories International, Inc., CRISPR Therapeutics AG Stock News

As of August 21, 2026, Charles River Laboratories International, Inc. had a $14.1 billion market capitalization, compared to the Life Sciences Tools & Services median of $3.0 million. Charles River Laboratories International, Inc.’s stock is up 48% in 2026, up 5.4% in the previous five trading days and up 84.98% in the past year.

Currently, Charles River Laboratories International, Inc. does not have a price-earnings ratio. Charles River Laboratories International, Inc.’s trailing 12-month revenue is $4.0 billion with a -6.0% net profit margin. Year-over-year quarterly sales growth most recently was -2.7%. Analysts expect adjusted earnings to reach $11.318 per share for the current fiscal year. Charles River Laboratories International, Inc. does not currently pay a dividend.

As of August 21, 2026, CRISPR Therapeutics AG had a $5.8 billion market cap, putting it in the 69th percentile of all stocks. CRISPR Therapeutics AG’s stock is up 13.5% in 2026, up 11.1% in the previous five trading days and up 12.12% in the past year.

Currently, CRISPR Therapeutics AG does not have a price-earnings ratio. CRISPR Therapeutics AG’s trailing 12-month revenue is $13.4 million with a % net profit margin. As of August 21, 2026, CRISPR Therapeutics AG has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.447 per share for the current fiscal year. CRISPR Therapeutics AG does not currently pay a dividend.

How We Compare Charles River Laboratories International, Inc. and CRISPR Therapeutics AG Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Charles River Laboratories International, Inc. and CRISPR Therapeutics AG’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Charles River Laboratories International, Inc. and CRISPR Therapeutics AG Stock Value Grades

Company	Ticker	Value
Charles River Laboratories International, Inc.	CRL	D
CRISPR Therapeutics AG	CRSP	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Charles River Laboratories International, Inc. has a Value Score of 24, which is Expensive. CRISPR Therapeutics AG has a Value Score of 8, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Charles River Laboratories International, Inc. or CRISPR Therapeutics AG has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Charles River Laboratories International, Inc. or CRISPR Therapeutics AG is the better investment when it comes to value.

Charles River Laboratories International, Inc. and CRISPR Therapeutics AG Growth Grades

Company	Ticker	Growth
Charles River Laboratories International, Inc.	CRL	B
CRISPR Therapeutics AG	CRSP	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Charles River Laboratories International, Inc. has a Growth Score of 77, which is Strong. CRISPR Therapeutics AG has a Growth Score of 7, which is Very Weak.

The Growth Grade Winner: Charles River Laboratories International, Inc.

As you can clearly see from the Growth Grade breakdown above, Charles River Laboratories International, Inc. has a more attractive growth grade than CRISPR Therapeutics AG. For investors who focus solely on how a company is growing relative to other companies in the same industry, Charles River Laboratories International, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Charles River Laboratories International, Inc. and CRISPR Therapeutics AG’s Quality Grades

Company	Ticker	Quality
Charles River Laboratories International, Inc.	CRL	C
CRISPR Therapeutics AG	CRSP	F

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Charles River Laboratories International, Inc. has a Quality Score of 59, which is Average. CRISPR Therapeutics AG has a Quality Score of 9, which is Very Weak.

The Quality Stock Winner: No Clear Winner

Neither Charles River Laboratories International, Inc. or CRISPR Therapeutics AG has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Charles River Laboratories International, Inc. or CRISPR Therapeutics AG is the better investment when it comes to quality.

Other Charles River Laboratories International, Inc. and CRISPR Therapeutics AG Grades

In addition to Growth, Quality and Value, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Charles River Laboratories International, Inc. and CRISPR Therapeutics AG pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Charles River Laboratories International, Inc. or CRISPR Therapeutics AG Stock?

Overall, Charles River Laboratories International, Inc. stock has a Value Score of 24, Growth Score of 77 and Quality Score of 59.

CRISPR Therapeutics AG stock has a Value Score of 8, Growth Score of 7 and Quality Score of 9.

Comparing Charles River Laboratories International, Inc. and CRISPR Therapeutics AG’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.